Deliver the Cure.

Using advanced lentiviral vector technology, we are at the forefront of rare disease and cancer treatment, redefining the possibilities of gene therapy.

About Santo

Santo Therapeutics is an innovative drug development company dedicated to advancing the next generation of lentiviral vector (LV) recombinant technology for in vivo gene therapy. With over 20 years of expertise in vector optimization and disease mechanism research, our research results have been published in esteemed international journals. In the field of cancer treatment, Santo employs gene-based natural therapies to reprogram cellular self-protection mechanisms, focusing on controlling tumor growth and enhancing patient health rather than merely eradicating tumor cells. Our goal is to provide a one-time treatment that delivers a lifelong cure through gene therapy.

Learn More

Core Technology

Santo is developing a next-generation LV specifically designed to meet clinical needs, providing a safe and effective method for gene therapy delivery. Concurrently, the company employs gene editing and other advanced technologies to establish diverse model platforms that facilitate drug development. Furthermore, Santo is developing a serum-free LV production system, aiming to enhance production efficiency through high-throughput screening technologies.

Learn More

The Santo Therapeutics' team is developing highly targeted fifth-generation lentiviral vectors based on clinical needs, enhancing the accuracy and safety of gene therapy.

STLenti®

The team at Santo Therapeutics is committed to creating a new type of carrier that is fully programmable, aimed at precisely treating specific tissues to ensure that the treatment is both safe and effective.

STPDX®

In response to clinical treatment needs, Santo Therapeutics is developing a fifth-generation vector that improves gene delivery efficiency and safety to specific target tissues through advanced programming.

STProd®

Research Pipeline

Santo Therapeutics' pipeline is positioned in the urgently demanded global market, focusing on the oncology field with significant market potential, including urgently needed gene therapies for conditions such as neurofibromas, meningiomas, and malignant mesotheliomas. Currently, the indications that Santo Therapeutics is focusing on essentially belong to a gap in drug availability.

Learn More

Leading Team

Founder (CEO)

Dr. Lu Zhou

Gene Therapy Scientist

Expert in NF Mechanisms

Multiple Award-Winning Drug Researcher

Honorary Chairman

Nick Rodgers

Former Chairman of Oxford Bio (OXB) and Destiny Pharma

Chief Technology Officer (CTO)

Dr. Fang Zhang

Lentiviral Vector Scientist

ex-Senior Researcher, GOSH, UCL

Chief Science Officer (CSO)

Dr. Da Mi

Assistant Professor, Tsinghua-IDG/McGowan Institute

PhD, Edinburgh; Postdoc, Yale

CMC Director

Liu Tie

Biopharmaceutical P&Q Expert

Senior Scientist, AstraZeneca

CMC Team Manager, Pfizer/BMS

Chief Financial Officer (CFO)

Die Li

Saïd Business School, University of Oxford

Private Equity Investment

Products and Services

Our objective is to create a supportive community environment that allows you to promptly access scientific information, expert advice, and opportunities for sharing experiences. At present, we offer the following services:

Scientific Consultation
Science Outreach Activities
Research Collaboration

For specific product and service details, please scan the QR code of our official account.